Mifomet

Active Ingredient:: Metformin Hydrochloride, Sitagliptin
Origin:: EU

Mifomet (Metformin Hydrochloride, Sitagliptin)

Q: What is Mifomet used for?

Mifomet is indicated for the treatment of type 2 diabetes mellitus in adults. It is prescribed when diet, exercise, and lifestyle modifications alone do not achieve adequate glycemic control, helping to lower blood glucose and HbA1c levels.

Q: How does Metformin and Sitagliptin work?

Metformin lowers glucose production by the liver and improves insulin sensitivity in muscle and fat tissue. Sitagliptin blocks the DPP‑4 enzyme, increasing levels of incretin hormones that stimulate insulin release and reduce glucagon secretion in a glucose‑dependent manner. Together they provide complementary glucose‑lowering effects.

Q: What is the usual dose of Mifomet?

The dose of Mifomet is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule for each patient.

Q: Is Mifomet safe in pregnancy or breastfeeding?

Safety of Mifomet during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare provider.

Q: How do I order Mifomet from GNH India?

To order Mifomet, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does Mifomet compare with other antidiabetic options?

Mifomet combines two established agents—metformin, a first‑line biguanide, and sitagliptin, a DPP‑4 inhibitor—into a single tablet, simplifying the regimen compared with taking separate pills. This fixed‑dose approach can improve adherence while delivering complementary mechanisms of action not seen with monotherapy.

Q: How should Mifomet be stored and handled?

Mifomet tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Q: How is Mifomet administered?

Mifomet is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

Q: What are the most serious risks to watch for while taking Mifomet?

The most serious risks include lactic acidosis (a rare but potentially fatal condition linked to metformin), severe hypoglycemia (especially when combined with other glucose‑lowering drugs), and pancreatitis associated with sitagliptin. Patients should seek immediate medical attention if they experience symptoms such as unexplained muscle pain, rapid breathing, severe abdominal pain, or persistent vomiting.

Q: Who should not use Mifomet?

Mifomet is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease or acute heart failure.

Metformin Hydrochloride and Sitagliptin, the active ingredients in Mifomet, are a combination of a biguanide and a DPP‑4 inhibitor presented as tablets for oral use. It treats type 2 diabetes mellitus in adults when diet and exercise alone are insufficient.

GNH India supplies Mifomet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bausch Health Poland Sp. Z O.O.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mifomet, a fixed‑dose combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves overall glycemic control and reduces HbA1c levels.
Patients inadequately controlled on metformin alone: adds DPP‑4 inhibition for additional glucose lowering.
Adults requiring combination therapy: simplifies regimen by combining two agents in one tablet.

How It Works

Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin levels that promote glucose‑dependent insulin secretion and suppress glucagon release, together achieving better blood glucose regulation.

Side Effects

Mifomet may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
Headache: mild to moderate intensity.
Mild hypoglycemia: especially when used with other glucose‑lowering agents.
Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects

Lactic acidosis: a rare but life‑threatening condition linked to metformin.
Severe hypoglycemia: can occur with concomitant sulfonylureas.
Pancreatitis: inflammation of the pancreas associated with sitagliptin.
Allergic reactions: rash, pruritus, or angioedema.
Hepatic failure: rare liver dysfunction requiring immediate medical attention.

Precautions & Warnings

Before prescribing Mifomet, clinicians should consider several safety factors.

Renal function: assess eGFR and monitor periodically.
Lactic acidosis risk: avoid in patients with severe renal impairment.
Hepatic disease: use with caution in patients with liver dysfunction.
Pregnancy and lactation: safety not established; weigh benefits against risks.
Known hypersensitivity: contraindicated in patients allergic to metformin or sitagliptin.
Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Mifomet can interact with various medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): metformin accumulation risk.
MAO inhibitors: increased risk of hypoglycemia.
Strong CYP3A4 inhibitors: may raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely)

Sulfonylureas: additive hypoglycemia risk.
Thiazolidinediones: enhanced glucose‑lowering effect.
Iodinated contrast media: transient renal function decline affecting metformin clearance.

Frequently Asked Questions

Mifomet is indicated for the treatment of type 2 diabetes mellitus in adults. It is prescribed when diet, exercise, and lifestyle modifications alone do not achieve adequate glycemic control, helping to lower blood glucose and HbA1c levels.

Metformin lowers glucose production by the liver and improves insulin sensitivity in muscle and fat tissue. Sitagliptin blocks the DPP‑4 enzyme, increasing levels of incretin hormones that stimulate insulin release and reduce glucagon secretion in a glucose‑dependent manner. Together they provide complementary glucose‑lowering effects.

The dose of Mifomet is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule for each patient.

Safety of Mifomet during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare provider.

To order Mifomet, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mifomet combines two established agents—metformin, a first‑line biguanide, and sitagliptin, a DPP‑4 inhibitor—into a single tablet, simplifying the regimen compared with taking separate pills. This fixed‑dose approach can improve adherence while delivering complementary mechanisms of action not seen with monotherapy.

Mifomet tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Mifomet is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis (a rare but potentially fatal condition linked to metformin), severe hypoglycemia (especially when combined with other glucose‑lowering drugs), and pancreatitis associated with sitagliptin. Patients should seek immediate medical attention if they experience symptoms such as unexplained muscle pain, rapid breathing, severe abdominal pain, or persistent vomiting.

Mifomet is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease or acute heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.